Trials / Completed
CompletedNCT06126861
The Mass Balance Study of LP-168 in Healthy Subjects
The Mass Balance Study of [14C]LP-168 in Chinese Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi \[14C\]LP-168 in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]LP-168 | single dose of 150 mg/100 μCi \[14C\] LP-168, orally suspension at fasted state |
Timeline
- Start date
- 2023-12-25
- Primary completion
- 2024-02-02
- Completion
- 2024-03-13
- First posted
- 2023-11-13
- Last updated
- 2024-03-15
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06126861. Inclusion in this directory is not an endorsement.